ABUS
Income statement / Annual
Last year (2024), Arbutus Biopharma Corporation's total revenue was $6.17 M,
a decrease of 65.98% from the previous year.
In 2024, Arbutus Biopharma Corporation's net income was -$69.92 M.
See Arbutus Biopharma Corporation,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$6.17 M |
$18.14 M |
$39.02 M |
$10.99 M |
$6.91 M |
$6.01 M |
$5.90 M |
$10.70 M |
$1.50 M |
$24.87 M |
| Cost of Revenue |
$0.00
|
$73.70 M
|
$1.43 M
|
$1.75 M
|
$47.48 M
|
$57.60 M
|
$57.90 M
|
$62.70 M
|
$61.30 M
|
$51.51 M
|
| Gross Profit |
$6.17 M
|
-$55.56 M
|
$37.59 M
|
$9.24 M
|
-$40.57 M
|
-$51.59 M
|
-$52.00 M
|
-$52.00 M
|
-$59.80 M
|
-$26.63 M
|
| Gross Profit Ratio |
1
|
-3.06
|
0.96
|
0.84
|
-5.87
|
-8.58
|
-8.81
|
-4.86
|
-39.87
|
-1.07
|
| Research and Development Expenses |
$54.04 M
|
$73.70 M
|
$84.41 M
|
$65.50 M
|
$47.48 M
|
$57.60 M
|
$57.90 M
|
$62.70 M
|
$61.30 M
|
$51.51 M
|
| General & Administrative Expenses |
$22.11 M
|
$22.48 M
|
$17.83 M
|
$17.14 M
|
$14.72 M
|
$17.73 M
|
$16.00 M
|
$16.10 M
|
$39.40 M
|
$26.44 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$22.11 M
|
$22.48 M
|
$17.83 M
|
$17.14 M
|
$14.72 M
|
$17.73 M
|
$16.00 M
|
$16.10 M
|
$39.40 M
|
$26.44 M
|
| Other Expenses |
$6.35 M
|
$0.00
|
$2.23 M
|
$1.87 M
|
$1.98 M
|
$2.03 M
|
$7.30 M
|
$2.20 M
|
$2.50 M
|
-$770,000.00
|
| Operating Expenses |
$82.49 M
|
$96.24 M
|
$102.24 M
|
$82.64 M
|
$64.18 M
|
$77.36 M
|
$76.10 M
|
$80.80 M
|
$101.80 M
|
$78.53 M
|
| Cost And Expenses |
$82.49 M
|
$96.24 M
|
$102.24 M
|
$82.64 M
|
$64.18 M
|
$77.36 M
|
$76.10 M
|
$80.80 M
|
$101.80 M
|
$78.53 M
|
| Interest Income |
$6.59 M
|
$5.69 M
|
$2.19 M
|
$127,000.00
|
$741,000.00
|
$2.11 M
|
$3.00 M
|
$1.54 M
|
$1.39 M
|
$674,000.00
|
| Interest Expense |
$137,000.00
|
$459,000.00
|
$1.73 M
|
$2.86 M
|
$4.01 M
|
$2.11 M
|
$200,000.00
|
$261,000.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.38 M
|
$1.40 M
|
$1.43 M
|
$1.75 M
|
$1.98 M
|
$2.03 M
|
$2.18 M
|
$2.03 M
|
$1.09 M
|
$589,000.00
|
| EBITDA |
-$68.40 M |
-$70.99 M |
-$61.86 M |
-$71.64 M |
-$57.81 M |
-$147.32 M |
-$58.95 M |
-$106.45 M |
-$488.07 M |
-$76.72 M |
| EBITDA Ratio |
-11.08
|
-3.91
|
-1.59
|
-6.52
|
-8.36
|
-24.51
|
-9.99
|
-9.95
|
-325.38
|
-3.08
|
| Operating Income Ratio |
-12.37
|
-4.31
|
-1.68
|
-6.69
|
-8.36
|
-23.97
|
-15.22
|
-10.36
|
-327.73
|
-4.11
|
| Total Other Income/Expenses Net |
$6.40 M
|
$5.25 M
|
$444,000.00
|
-$2.73 M
|
-$5.94 M
|
-$22.48 M
|
$28.44 M
|
$2.20 M
|
$2.47 M
|
$25.02 M
|
| Income Before Tax |
-$69.92 M
|
-$72.85 M
|
-$65.01 M
|
-$76.25 M
|
-$63.75 M
|
-$166.38 M
|
-$61.40 M
|
-$108.70 M
|
-$489.10 M
|
-$77.31 M
|
| Income Before Tax Ratio |
-11.33
|
-4.02
|
-1.67
|
-6.94
|
-9.22
|
-27.68
|
-10.41
|
-10.16
|
-326.07
|
-3.11
|
| Income Tax Expense |
$0.00
|
$0.00
|
$4.44 M
|
$1.10 M
|
$1.47 M
|
-$12.66 M
|
-$4.30 M
|
-$24.30 M
|
-$105.00 M
|
-$16.19 M
|
| Net Income |
-$69.92 M
|
-$72.85 M
|
-$69.46 M
|
-$77.35 M
|
-$65.21 M
|
-$153.72 M
|
-$57.10 M
|
-$84.40 M
|
-$384.10 M
|
-$61.12 M
|
| Net Income Ratio |
-11.33
|
-4.02
|
-1.78
|
-7.04
|
-9.43
|
-25.57
|
-9.68
|
-7.89
|
-256.07
|
-2.46
|
| EPS |
-0.38 |
-0.44 |
-0.46 |
-0.73 |
-0.86 |
-2.69 |
-1.03 |
-1.54 |
-7.24 |
-1.34 |
| EPS Diluted |
-0.38 |
-0.44 |
-0.46 |
-0.73 |
-0.86 |
-2.69 |
-1.03 |
-1.54 |
-7.24 |
-1.34 |
| Weighted Average Shares Out |
$185.61 M
|
$165.96 M
|
$150.94 M
|
$106.24 M
|
$75.84 M
|
$57.09 M
|
$55.30 M
|
$54.69 M
|
$53.05 M
|
$45.45 M
|
| Weighted Average Shares Out Diluted |
$185.61 M
|
$165.96 M
|
$150.94 M
|
$106.24 M
|
$75.84 M
|
$57.09 M
|
$55.30 M
|
$54.72 M
|
$53.05 M
|
$45.46 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
